Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

Exclusion Criteria

• •1. Previous transplant.
• •2. Multiorgan or split liver transplant other than with a right trisegment.
• •3. Living donor transplant.
• •4. Donor liver from a donor positive for antibody against hepatitis C.
• •5. Donor liver from a non-heart-beating donor.
• •6. Liver failure due to autoimmune disease.
• •7. Fulminant liver failure.
• •8. Hepatitis B infection as defined by the presence of HbSAg or hepatitis-C infection with a genome other than genome 1.
• •9. Stage III or higher hepatocellular cancer.
• •10. History of malignancy except hepatocellular cancer, adequately treated in situ cervical carcinoma,adequately treated basal or squamous cell carcinoma of skin, or other cancer judged to have a 5-year risk of recurrence less than 10%.
• •11. Active systemic infection at the time of transplantation.
• •12. Clinically significant chronic renal disease.
• •13. Clinically significant cardiovascular or cerebrovascular disease.
• •14. Infection with human immunodeficiency virus.
• •15. Any investigational drug received within 6 weeks of study entry or any investigational vaccine received at any time.
• •16. Hypersensitivity to tacrolimus.
• •17. Unwillingness or inability to comply with study requirements.